Mutations of the Mitochondrial Holocytochrome c–Type Synthase in X-Linked Dominant Microphthalmia with Linear Skin Defects Syndrome  by Wimplinger, Isabella et al.
878 The American Journal of Human Genetics Volume 79 November 2006 www.ajhg.org
ARTICLE
Mutations of the Mitochondrial Holocytochrome c–Type Synthase
in X-Linked Dominant Microphthalmia with Linear Skin Defects
Syndrome
Isabella Wimplinger,* Manuela Morleo,* Georg Rosenberger, Daniela Iaconis, Ulrike Orth,
Peter Meinecke, Israela Lerer, Andrea Ballabio, Andreas Gal, Brunella Franco, and Kerstin Kutsche
The microphthalmia with linear skin defects syndrome (MLS, or MIDAS) is an X-linked dominant male-lethal disorder
almost invariably associated with segmental monosomy of the Xp22 region. In two female patients, from two families,
with MLS and a normal karyotype, we identiﬁed heterozygous de novo point mutations—amissense mutation (p.R217C)
and a nonsense mutation (p.R197X)—in the HCCS gene. HCCS encodes the mitochondrial holocytochrome c–type
synthase that functions as heme lyase by covalently adding the prosthetic heme group to both apocytochrome c and
c1. We investigated a third family, displaying phenotypic variability, in which the mother and two of her daughters carry
an 8.6-kb submicroscopic deletion encompassing part of the HCCS gene. Functional analysis demonstrates that both
mutant proteins (R217C and D197–268) were unable to complement a Saccharomyces cerevisiae mutant deﬁcient for the
HCCS orthologue Cyc3p, in contrast to wild-type HCCS. Moreover, ectopically expressed HCCS wild-type and the R217C
mutant protein are targeted to mitochondria in CHO-K1 cells, whereas the C-terminal–truncated D197–268mutant failed
to be sorted to mitochondria. Cytochrome c, the ﬁnal product of holocytochrome c–type synthase activity, is implicated
in both oxidative phosphorylation (OXPHOS) and apoptosis. We hypothesize that the inability of HCCS-deﬁcient cells
to undergo cytochrome c–mediated apoptosis may push cell death toward necrosis that gives rise to severe deterioration
of the affected tissues. In summary, we suggest that disturbance of both OXPHOS and the balance between apoptosis
and necrosis, as well as the X-inactivation pattern, may contribute to the variable phenotype observed in patients with
MLS.
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Microphthalmia with linear skin defects syndrome (MLS
[MIM#309801]), also known as “MIDAS” (microphthalmia,
dermal aplasia, and sclerocornea), is a rare X-linked dom-
inant condition characterized by unilateral or bilateralmi-
crophthalmia and linear skin defects—which are limited
to the face and neck, consisting of areas of aplastic skin
that heal with age to form hyperpigmented areas—in af-
fected females and in utero lethality for males. Additional
features in female patients include agenesis of the corpus
callosum, sclerocornea, chorioretinal abnormalities, infan-
tile seizures, congenital heart defect, mental retardation,
and diaphragmatic hernia.1 In the majority of cases, pa-
tients carry a chromosomal aberration that results in seg-
mental monosomy of the Xp22 chromosomal region (111
Mb). To date, eight patients with an apparently normal fe-
male karyotype have been described.2–6 The MLS minimal
critical region has been delineated to 610 kb in Xp22.2,
through breakpoint mapping of two X;Y translocations of
patients not affectedwithMLS and of the smallest deletion
characterized in a female with the typical MLS pheno-
type.7 Three genes are located in the critical interval, in-
cluding MID1, HCCS, and ARHGAP67 (ﬁg. 1A). MID1 is
mutated in Opitz G/BBB syndrome,8 whereas no disease-
associated mutations have yet been described for HCCS
andARHGAP6. TheARHGAP6 gene codes for a RhoGTPase–
activating protein (Rho GAP) that functions as a GAP for
the small GTPase RhoA, as well as a protein implicated
in reorganization of the actin cytoskeleton.9,10 HCCS en-
codes a mitochondrial holocytochrome c–type synthase,
also known as “heme lyase,” composed of 268 aa.11,12 It
catalyzes the covalent attachment of heme to both apo-
cytochrome c and c1, the precursor forms, thereby lead-
ing to the mature forms, holocytochrome c and c1, which
are necessary for proper functioning of the mitochondrial
respiratory chain.13,14 In addition to the well-known role
of cytochrome c in oxidative phosphorylation (OXPHOS),
cytochrome c is released from mitochondria in response
to a variety of intrinsic death-promoting stimuli that, in
turn, result in caspase-dependent cell death, namely
“apoptosis.”15
The majority of patients display the classic phenotypic
features of MLS; however, a high intra- as well as inter-
familial clinical variability that is not correlated with the
extent of the chromosomal deletion has been reported.
For example, a few patients show the typical skin defects
but no ocular manifestation,2,16–18 whereas others present
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Figure 1. Minimal MLS critical region and haplotype analysis of the family of patient II.7. A, Schematic representation of the minimal
MLS critical region (610 kb) in Xp22.2, deﬁned by the breakpoints of patients BA333 and BA325 (jagged lines). The ﬁgure is not drawn
to scale. The uppermost arrows show the orientation of genes within the critical region. The position of DNA marker loci previously
mapped in this region is shown. B, Haplotype analysis of six representative polymorphic markers in Xp22.2-p22.13 in the family of
patient II.7. Whereas markers DXS7108, CxM06, CxM09, and SNP rs5901444—(CGG)n—are positioned in the MLS critical region and
indicated in panel A, loci DXS8019 and DXS999 are located centromeric to the critical region. The polymorphic (CGG)n repeat is located
in the HCCS 5′ UTR, and the respective repeat length is given. Alleles are shown below the pedigree symbols. del p Deletion of one
allele. The haplotype shared by the affected sisters (II.1 and II.7) and their mother (I.1) is boxed. Both patients II.7 and II.1 carry
only the paternal allele, with eight CGG repeats, whereas the unaffected sister (II.5) is heterozygous for the trinucleotide repeat.
Segregation analysis showed that the three brothers (II.2, II.4, and II.6) and the unaffected sister (II.5) carry a different maternal
haplotype than do II.1 and II.7.
with only eye abnormalities, and dermal lesions are ab-
sent.19–21 It has been suggested that the pattern of X in-
activation may play a role in the development of the var-
ious symptoms seen in patients with MLS.22,23
The identiﬁcation of the genetic defect for MLS has
been hampered by the absence of patients with a full-
blown MLS phenotype and a normal karyotype. In 2005,
Morleo and colleagues5 undertook the ﬁrst attempt at
a detailed characterization of four patients with MLS and
no obvious chromosomal rearrangements. With use of
FISH with genomic clones spanning the MLS critical
region and a genomewide analysis with BAC microar-
rays, no microdeletion or duplication could be detected
in these patients. Similarly, direct sequencing of coding
regions and exon-intron boundaries of MID1, HCCS, and
ARHGAP6 revealed no pathogenic sequence alteration or
small rearrangement that would suggest that these pa-
tients carry cryptic rearrangements that had been missed
by the techniques applied.5
Material and Methods
Patients
We examined the family of proband II.7. She is the youngest
daughter of healthy and unrelated parents. There is no maternal
history of skin defect or any other pathology, nor is there any
family history of genetic disease or malformations. The couple
has three healthy sons and one healthy daughter. Three preg-
nancies ended with spontaneous abortions early in the ﬁrst tri-
mester (ﬁg. 1B). The proband was born with a left anophthalmia,
sclerocornea, and lateral skin defect on her cheek. At age 6 mo,
she presented with junctional ectopic tachycardia, which was
successfully treated by catheter ablation. At age 3 years, she had
normal psychomotor development.
Her eldest sister (II.1) was born with the following manifesta-
tions: a left opaque cornea, congenital glaucoma with total an-
terior synechia, and a white anterior cataract. On the right side,
she presented with corneal leukoma, which has resolved with
time. She showed no other malformations, and her psychomotor
development is normal. The couple had another baby girl, with
bilateral anophthalmia, who died at age 6 h from complications
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Figure 2. A submicroscopic deletion encompassing part of the HCCS gene is present in three members of the family of patient II.7.
A, Southern blot hybridized with a probe covering the HCCS 5′ UTR and coding region. Genomic DNA samples of patient II.7 and controls
were digested with SpeI and EcoRV (left), NdeI and SacI (middle), and TaqI (right). Cp female control; C (5X)p human cell line with
ﬁve X chromosomes. Various fragments of altered sizes (red arrows) were observed in II.7. B, Relative quantiﬁcation of copy numbers
of HCCS exons 1–4, by real-time PCR on genomic DNA of individuals I.1, II.1, and II.7. BA637 has MLS and displays monosomy of the
Xp22 region.5 Values of HCCS exons 1–3 in II.7, II.1, and I.1 are comparable to that of a haploid sample. C, Schematic representation
of part of the MLS critical region (top). MID1 and HCCS genes are indicated by long arrows, and primers used for junction fragment
ampliﬁcation are indicated by short arrows. Exons 1a and 1b of MID1 are represented by bars, exons of HCCS by black boxes. Jagged
orange lines indicate deletion breakpoints. E p EcoRV; N p NdeI; S p SpeI; Sac p SacI; T p TaqI. Bottom left panel, Ampliﬁcation
of a junction fragment from genomic DNA of I.1, II.1, and II.7 but not from a control (C). M p DNA marker. Bottom right panel, Part
of the DNA sequence electropherogram of the rearrangement-speciﬁc junction fragment. The deletion breakpoint is indicated by a jagged
orange line. The 8.6-kb deletion encompasses HCCS exons 1–2, part of exon 3, and exons 1a and 1b of MID1.
of a left diaphragmatic hernia. High-resolution karyotype of both
affected sisters was normal.
Patient MS1, a 5-year-old girl, is the ﬁrst child of healthy par-
ents. Pregnancy was uneventful, and delivery was without any
complication; birth measurements were in the upper-normal
range. The newborn showed bilateral microphthalmia (more se-
vere on the right), with bilateral cloudy and vascular cornea. In
addition, linear and patchy erythrodermia of the patient’s cheeks
and right lateral neck was noticed immediately after birth. At age
3 mo, complete sclerocornea was noticed; however, erythroder-
mia had faded gradually. Reexamination at age 6 mo revealed
poor vision but only verymild facial erythrodermia andonlymild
developmental delay. Cranial magnetic-resonance-imaging stud-
ies at age 1 year demonstrated hypoplasia of the corpus callosum,
lack of the septum pellucidum, and slightly dilated third ventri-
cle. The patient’s further development was characterized by nor-
mal growth, mild-to-moderate developmental delay, and very se-
vere visual impairment. The happy-natured girl is now able to
speak short sentences.
Patient MS2, a 9-year-old girl, was born to healthy unrelated
parents after an uneventful pregnancy. Birth measurements were
within the normal range. After birth, she presented with bilateral
microphthalmia and sclerocornea. A small mandible, a single pal-
mar crease, and a sandal gap but no erythematous skin lesions
were noticed. At the end of her 1st year of life, she developed
idiopathic ventricular tachycardia, which was converted to nor-
mal sinus rhythm by amiodaron and ajmalin. After extubation
and end of sedation, she suffered an occlusion of her right arteria
cerebri media and subsequently developed hemiparesis on the
left side. Neurologic symptoms declined after physiotherapy. At
age 8 years, she suffered a sole tonic-clonic seizure.
Our ethics committees approved this study, and written in-
formed consent was obtained from all participants or their legal
guardians.
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Figure 3. Point mutations in HCCS in two patients with MLS. A–C, Photographs of patients MS1 and MS2. A, Linear skin defects located
on the face and neck of patient MS1 at birth. B, Microphthalmia of the right eye and bilateral sclerocornea of patient MS1 at age 4
years. Linear skin defects have completely disappeared. C, Patient MS2, at age 8 years, with bilateral microphthalmia and sclerocornea.
No linear skin defects were noted at birth. D, Sequence electropherograms of part of HCCS exons from genomic DNA of patients MS1
and MS2. Nucleotide triplets and encoded amino acids are indicated. Patient MS1 is heterozygous for the c.589CrT mutation (p.R197X)
(left panel) in exon 6, whereas the heterozygous mutation c.649CrT (p.R217C) (right panel) in exon 7 was found in patient MS2. E,
Partial amino acid–sequence alignment of heme lyases from various species. The position of amino acids is given. Evolutionarily conserved
residues are shown in bold. The invariant arginine at position 217, which is altered to cysteine in patient MS2, is shaded in gray. HCCS1
indicates speciﬁcity of the heme lyase for cytochrome c1. Hs p Homo sapiens; Mm1 p Mus musculus; Rr p Rattus norvegicus; Cf p
Canis familiaris; Pt p Pan troglodytes; Mm p Macaca mulatta; Bt p Bos taurus; Ca p Candida albicans; Sc p S. cerevisiae; Sp p
Schizosaccharomyces pombe; Nc p Neurospora crassa; Ce p Caenorhabditis elegans.
Mutation Analysis, X-Inactivation Assay, and Real-Time
PCR
Genomic DNA was isolated by standard procedures.We ampliﬁed
the coding region (exons 2–7) of HCCS (GenBank accession num-
ber NM_005333), including the ﬂanking intronic sequences, from
genomic DNA. Primer sequences and PCR conditions are available
on request. PCR products were directly sequenced with the Big
Dye Terminator ready reaction kit (PE Applied Biosystems) on an
ABI Prism 377 (PE Applied Biosystems).
Examination of the methylation pattern at the androgen re-
ceptor (AR) locus was performed according to the procedures of
Allen et al.,24 with minor modiﬁcations. For each DNA sample,
two reactions were prepared: in the ﬁrst, 400 ng of DNA was
digested with 8 U HpaII in a total volume of 10 ml, for 30 min at
37C; in the second, 400 ng DNA was incubated with the enzyme
reaction buffer, but without enzyme. To conﬁrm complete di-
gestion, DNA samples from a male and from a female with uni-
lateral X inactivation were included as controls. Subsequent PCR
ampliﬁcation of the AR locus with primers AR-A_FAM (5′-CTTTC-
CAGAATCTGTTCCAG-3′; labeled with 5′ FAM) and AR-B (5′-AAG-
GTTGCTGTTCCTCATC-3′) was performed in a 25-ml reaction vol-
ume for 40 ng of the undigested DNA and in a total of 50 ml
volume for 250 ng of HpaII-cleaved DNA. The PCR contained
both oligonucleotide primers at a concentration of 0.4 mM each,
0.2 mM dinucleotide triphosphates (dNTPs), and 0.5 U Taq poly-
merase (QIAGEN). Samples were denatured, with use of a PTC
thermocycler (MJ Research), at 95C for 3 min, followed by 35
cycles at 95C for 1 min, at 55C for 1 min, and at 72C for 1
min, followed by a ﬁnal incubation at 72C for 10min. A quantity
of 0.4–0.8 ml of the amplicons was mixed with 20 ml deionized
formamide and 0.4 ml TAMRA (red ﬂuorescent dye) Size Standard
(PE Applied Biosystems) and was denatured at 95C for 5 min.
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Figure 4. HCCS mutant proteins are not able to complement S.
cerevisiae CYC3 deﬁciency. A, Functional complementation of the
S. cerevisiae strain B-8025. B-8025 was transformed with human
wild-type HCCS (HCCS WT), the mutants D197–268 and R217C, or
yeast CYC3 (Cyc3p) expression constructs and was grown on min-
imal medium. Transformants were grown in liquid minimal medium,
and aliquots of 5 ml of saturated and diluted cultures were spotted
on glycerol medium containing copper (to induce expression of
GST-fusion proteins) and were incubated for 5 d at 30C. The top
row shows spots of saturated cultures, and the middle and bottom
rows show spots of dilutions; dilution rates are indicated to the
left of the ﬁgure. Note partial restoration of growth by Cyc3p and
wild-type HCCS, whereas no growth was observed for the untrans-
formed strain or that expressing HCCS D197–268 or HCCS R217C.
In parallel, all strains were also spotted on plates with glucose-
containing minimal medium and showed normal growth (data not
shown). Strain B-7553 served as wild-type growth control. B, Ex-
pression of GST-HCCS–fusion proteins determined by western blot-
ting. Expression of GST-HCCS R217C–, D197–268–, wild-type–, and
GST-Cyc3p–fusion proteins in yeast strain B-8025, grown in min-
imal medium with copper, was demonstrated by immunoblotting
(top panel), whereas, in strain B-8025 grown in glycerol-containing
medium, only GST-HCCS wild-type– and GST-Cyc3p–fusion proteins
were expressed (lower panel). B-8025 transformed with the GST-
HCCS D197–268 or GST-HCCS R217C construct did not grow under
this condition.
PCR products were analyzed on an ABI Prism 310 Genetic Ana-
lyzer (PE Applied Biosystems). Data were taken as a ratio of peak
areas of the shorter-to-longer alleles.
Real-time quantitative PCR on genomic DNA was performed
using an ABI Prism 7000 (PE Applied Biosystems) in a 96-well
optical plate, with a ﬁnal reaction of 20 ml. All reactions were
prepared with 10 ml of 2# SYBR green I ﬂuorescent dye PCR
Master Mix and 400 nM forward and reverse primers. Primers for
real-time experiments were designed using the Primer Express
software, in accordance with the PE Applied Biosystems guide-
lines; primers sequences are available on request. The RPP30 gene
(GenBank accession number NM_006413) coding for a ribonu-
clease P was used as an internal reference. A total of 100 ng of
DNA was used as a template for each sample; each was analyzed
in quadruplicate. Thermal cycling conditions included a prerun
of 2 min at 50C and of 10 min at 95C. Cycle conditions were
40 cycles at 95C for 15 s and at 60C for 1 min, in accordance
with the PCR protocol (PE Applied Biosystems). Relative quan-
tiﬁcation of exon-copy numbers on genomic DNAwas performed
using the comparative threshold cycle (ddCt) method: the start-
ing copy number of exons in patients was determined in com-
parison with the known copy number of the calibrator sample
(healthy male control), with use of the formula
ddCtp dCt HCCS (patient with MLS)
dCt RPP30 (patient with MLS)
dCt HCCS (healthy male)
dCt RPP30 (healthy male) .
The relative exon-copy number was calculated by the expression
that is of ∼2 for a diploid sample and ∼1 for a∧2  (ddCt SE)
haploid sample.
Haplotype and SNP Analysis
Haplotype analysis of family members of patient II.7 was per-
formed using ﬁve polymorphic microsatellite markers (tel-
DXS7108-CxM06-CxM09-DXS8019-DXS999-cen) in the Xp22.2-
p22.13 region, which contains theHCCS gene. PCR productswere
ampliﬁed using FAM (blue ﬂuorescent)–labeled primers, follow-
ing standard methods, and were electrophoresed on an ABI Prism
3100 Genetic Analyzer. Results were processed by GENESCAN
software (PE Applied Biosystems).
For analysis of polymorphism rs5901444, exon 1 containing
the trinucleotide CGG repeat was ampliﬁed using forward (5′-
CCTGCCACCGCCACATTTTG-3′) and reverse (5′-ATGAATAGGA-
ATTCGAAGAAACGAAGG-3′) primers. The PCR contained both
primers, each at a concentration of 0.2 mM, 0.2 mM dNTPs, and
1 U AmpliTaq Gold (PE Applied Biosystems), in a total volume
of 30 ml. Samples were ampliﬁed using a GeneAmp PCR System
9700 thermocycler (PE Applied Biosystems), with an initial de-
naturation at 95C for 7 min and 35 cycles at 98C for 1 min, at
58C for 1 min, and at 72C for 1 min.
RT-PCR
Total RNA was extracted from Epstein Barr virus–transformed
lymphoblastoid cells of patient MS1 with the RNeasy kit (QIA-
GEN), according to the manufacturer’s instructions. For ﬁrst-
strand cDNA synthesis, 1 mg of total RNA was reverse transcribed
by using the Omniscript RT Kit (QIAGEN) and randomhexamers,
according to the protocol provided. Of each ﬁrst-strand reaction,
1 ml cDNA was taken as template in PCRs, with use of Advantage
cDNA-Polymerase Mix (BD Biosciences Clontech) and primers
HCCS_RT_4F (5′-ATATCATTAGAATTCACAATCAG-3′) and HCCS_
RT_3R (5′-AAACTGCAAGGTACAACACAAGTC-3′). The PCR con-
dition was as follows: 35 cycles, each comprising 15 s at 95C, 10
s at 58C, and 40 s at 72C, with an initial denaturation at 95C
for 3 min.
Southern-Blot Analysis
For Southern-blot analysis, 10 mg of genomic DNA was digested
with the appropriate restriction enzymes: SpeI and EcoRV (double
digestion), NdeI and SacI (double digestion), and TaqI. DNA was
separated by electrophoresis in 0.8% agarose gel, was transferred
to Hybond-N (Amersham), and was hybridized to a probe cov-
ering the coding and the 5′ UTR regions of the HCCS transcript.
This probe was generated by RT-PCR on cDNA obtained from
lymphoblastoid cell lines, with use of primers RTF1 (5′-CGTGAA-
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Figure 5. Targeting of ectopically expressed HCCS wild-type and mutant proteins to mitochondria. Subcellular localization of different
N-terminally HA-tagged HCCS proteins ectopically expressed in CHO-K1 cells (A, D, and G) and staining of endogenous mitochondria
by MitoTracker (B, E, and H) are shown. HA-tagged HCCS wild-type protein (A [green]) is targeted to mitochondria (B [red]), as shown
by colocalization with the MitoTracker (C [yellow]). Similarly, HA-tagged HCCS R217C mutant protein (D [green]) shows a mitochondrial
(E [red]) distribution (F [yellow]). In contrast, the truncated HCCS D197–268 protein is diffusively dispersed in the cell (G), and the
two ﬂuorescence patterns (G and H) show no overlap (I). The scale bars represent 10 mm.
GTCACTGCTGCTCTG-3′) and RTR1 (5′-TCTGAAACAGTGCTTT-
ACGAGGTC-3′).
Generation of N- and C-Terminal–Tagged HCCS Constructs
HCCS cDNA clone DKFZp779I1858 (GenBank accession number
CR749578) was provided by the RZPD German Resource Center
for Genome Research (Berlin). The DNA insert of this cDNA clone
was sequenced by SP6 and T7 primers and primer walking (primer
sequences are available on request). Wild-type HCCS and HCCS
(D197–268) cDNA inserts were generated using speciﬁc PCR prim-
ers and the DKFZp779I1858 clone as template. TheHCCS (R217C)
insert was established by PCR-mediated mutagenesis.25 Puriﬁed
PCR products were cloned into pENTR/D-TOPO (Invitrogen) ac-
cording to the protocol provided. Constructs were sequenced for
integrity and then were used for cloning the HCCS-coding region
into plasmids pcDNA-DEST53 (N-terminal EGFP epitope [Invi-
trogen]), pcDNA-DEST47 (C-terminal EGFP epitope [Invitrogen]),
pMT2SM-HA-DEST (N-terminal HA epitope), and pcDNA3.2/V5-
DEST (C-terminal V5 epitope [Invitrogen]) via left-right reaction,
following the manufacturer’s instructions. Plasmid pMT2SM-HA-
DEST was generated by blunt-end ligation of the GATEWAYClon-
ing Reading Frame Cassette C (Invitrogen) into themultiple clon-
ing site of vector pMT2SM-HA.
Generation of Yeast-Expression Constructs
All yeast-expression constructs were generated in pYEX4Tps,which
drives expression of the glutathione-S-transferase (GST)–fusion
proteins from the Saccharomyces cerevisiae CUP1 promoter and
carries the selectable markers leu2-d, URA3, and Ampr. To generate
pYEX4Tps-HCCS wild type and pYEX4Tps-HCCS D197–268, PCR
products were ampliﬁed by using speciﬁc PCR primers and the
DKFZp779I1858 clone as template. pYEX4Tps-HCCS-R217C was
established by PCR-mediated mutagenesis.25 After puriﬁcation of
PCR products, each amplicon was restricted with BamHI andNotI
and was cloned unidirectionally into pYEX4Tps. To establish the
control construct pYEX4Tps-CYC3, a PCR product was ampliﬁed
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Figure 6. Skewed X inactivation in females with an HCCS mutation. X-chromosome inactivation determined by ampliﬁcation of an AR-
sequence polymorphism and digestion of genomic DNA isolated from lymphocytes with HpaII (indicated with plus [] and minus []
signs, respectively). The ratio of the X-inactivation pattern is given below the respective pedigree symbol. All females carrying an HCCS
mutation show nonrandom or extremely skewed X inactivation (patient MS1 in panel A; patient MS2 in panel B; and II.1, II.7, and
their mother [I.1] in panel C). D, Part of the DNA sequence electropherogram of HCCS exon 6, obtained from an RT-PCR amplicon of
patient MS1. Only the wild-type allele (c.589C) (arrow) is expressed in her lymphoblastoid cells.
by using speciﬁc primers and pAB256 carrying yeast CYC3 as
template. Subsequently, the amplicon was cloned as BamHI-NotI
fragment into pYEX4Tps. Primer sequences and PCR conditions
are available on request. All constructs were sequenced for integ-
rity, and large and pure amounts of plasmid DNA were prepared
by using a plasmid maxikit (QIAGEN).
Immunoﬂuorescence
CHO-K1 cells were cultured on ﬁbronectin-coated (10 mg/ml) cov-
erslips in F12-Ham’sNutrientMixture supplementedwith10%fetal
calf serum, 1% L-glutamine, and penicillin-streptomycin, at 37C
in 5% CO2. Cells were transfected with pcDNA-DEST53-HCCSwild
type, pcDNA-DEST53-HCCS R217C, pcDNA-DEST53-HCCS D197–
268, pcDNA-DEST47-HCCS wild type, pcDNA-DEST47-HCCS
R217C, pcDNA-DEST47-HCCS D197–268, pMT2SM-HA-DEST-
HCCS wild type, pMT2SM-HA-DEST-HCCS R217C, pMT2SM-
HA-DEST-HCCS D197–268, pcDNA3.2/V5-DEST-HCCS wild type,
pcDNA3.2/V5-DEST-HCCS R217C, and pcDNA3.2/V5-DEST-HCCS
D197–268 (each with 1 mg of DNA), with use of Lipofectamine2000
reagent (Invitrogen) according to the manufacturer’s protocol, and
were incubated overnight. The next day, cells were incubated in
normal growth medium supplemented with 50 nM MitoTracker
Red CMXRos (Invitrogen) for 20 min at 37C, were rinsed in PBS,
and were ﬁxed with 4% paraformaldehyde in PBS. After washing
three times with PBS, EGFP-transfected cells on coverslips were
directly mounted in glycerol gelatin (Sigma). Cells transfectedwith
HA- or V5-tagged HCCS constructs were incubated in permeabili-
zation/blocking solution (2% BSA, 3% goat serum, and 0.5% Non-
idet P-40 in PBS) for 60 min. Subsequently, HA- and V5-tagged
HCCS proteins were detected with rat monoclonal anti-HA-Flou-
rescein antibody (1.25 mg/ml) (Roche) andmousemonoclonal anti-
V5-FITC antibody (2.0 mg/ml) (Invitrogen), respectively, both di-
luted in antibody solution (3% goat serum and 0.1% Nonidet
P-40 in 1# PBS). After extensive washing with PBS, cells were
mounted in glycerol gelatin on microscopic slides. Images were
acquired with use of a Zeiss Axiovert 200 M confocal microscope
equipped with a 63# Planapochromat/1.4 DIC lens.
Yeast-Complementation Studies
For complementation studies, we used S. cerevisiae strain B-8025
(MATa can1-100 CYC1 cyc3-D cyc7-D::CYH2 cyh2 his3-D1 leu2-
3,112 trp1-289), which carries a deletion of CYC3,26 as well as B-
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7553 (MATa can1-100 CYC1 cyc7::CYH2 cyh2 his3-D1 leu2-3,112
trp1-289) as a growth control.27 Both B-8025 and B-7553 carry a
deletion of CYC7, which encodes cytochrome c1, one of the two
yeast cytochrome c proteins. Strains lacking CYC3 but still har-
boring CYC7 may still show residual respiratory growth due to
conversion of apocytochrome c1 to its holoform by the second
yeast heme lyase Cyt2p. Thus, the CYC3 mutant strain lacking
CYC7 is not able to grow at all on nonfermentable carbon sources
and needs complementation to show respiratory growth.
Yeast cells were maintained in complete medium (YPD). Trans-
formation of cells was done by the standard lithium-acetatemeth-
od. Positive transformants were selected by growth in minimal
medium, supplemented with 2% glucose but lacking leucine.Col-
onies that showed growth under this condition were grown in
liquid minimal medium until saturation and subsequently were
tested for growth on nonfermentable carbon sources (YPG me-
dium containing 3% glycerol, 2% peptone, 1% yeast extract, 2%
agar, and 0.2 mM CuSO4). Therefore, we generated two dilutions
(0.6-fold and 0.2-fold) from a saturated culture of each strain and
spotted 5 ml of these cultures on YPG plates and in parallel, as
growth control, on plates containing minimal medium with glu-
cose. Plates were incubated for 5 d at 30C.
Immunoblotting
Expression of various GST-HCCS and GST-CYC3–fusion proteins
was conﬁrmed by immunoblotting of lysates from saturated yeast
cultures (grown in minimal medium or YPG medium with cop-
per) with use of horseradish peroxidase–conjugated goat polyclo-
nal anti-GST antibody (0.3 mg/ml) (Amersham Pharmacia Biotech).
Results
Weexamined a family inwhich the youngest daughter (II.7)
shows the classic MLS phenotype and a normal karyotype.
However, a pathogenic mutation in MID1, ARHGAP6, and
HCCS in patient II.7 has not yet been identiﬁed.5 The older
sister (II.1) presents a milder phenotype, a third affected
daughter (II.3) died at age 6 h, and three spontaneous abor-
tions were also reported (ﬁg. 1B). The mother has no ob-
vious signs of MLS, although we cannot exclude the pres-
ence of skin lesions early in infancy that disappeared over
time; the examination with a UV light was not possible. In
an attempt to ﬁnd a microdeletion within the MLS critical
region, we performed segregation analysis using polymor-
phic markers within the HCCS gene (CGG repeat of SNP
rs5901444) and from regions nearby (DXS7108, CxM06,
CxM09, DXS8019, and DXS999). For SNP rs5901444,which
is located in the 5′ UTR of HCCS, the mother carries seven
CGG repeats, whereas the father has eight (ﬁg. 1B). Re-
markably, both patients (II.7 and II.1) carry only the pa-
ternal allele with eight CGG repeats, which suggests that
the mother is hemizygous rather than homozygous for this
repeat (ﬁg. 1B). Segregation analysis showed that the two
affected individuals carry a different maternal haplotype
than do their four unaffected siblings (ﬁg. 1B). To identify
a submicroscopic deletion, we performed Southern-blot
analysis with cDNA probes complementary to the HCCS 5′
UTR and coding region, using genomic DNA of patient II.7
digested with various enzymes. In addition to the expected
pattern, we identiﬁed aberrant bands in the patient com-
pared with control samples, which suggests the presence of
a heterozygous cryptic rearrangement involving the HCCS
gene (ﬁg. 2A).We used real-time PCR for comparativequan-
tiﬁcation of copy numbers of HCCS exon 1–7 amplicons
on genomic DNA of patient II.7, her sister (II.1), and the
asymptomatic mother (I.1). The relative copy number of
HCCS exons 1–3 was comparable to a haploid sample,
whereas that of exons 4–7 was comparable to a diploid
sample in the three females (ﬁg. 2B). We subsequently am-
pliﬁed a 4,764-bp breakpoint-spanning PCR product from
the DNA of patients II.1 and II.7 and their mother (ﬁg. 2C).
Direct sequencing of the junction fragment revealed the
presence of an 8.6-kb deletion comprising HCCS exons 1
and 2, the ﬁrst 83 bp of exon 3, the 5′ untranslated exons
1a and 1b of MID1, as well as the respective intronic se-
quences in I.1, II.1, and II.7 (ﬁg. 2C). This deletion was
absent in the three males (II.2, II.4, and II.6) and in the
unaffected female sibling (II.5) of the proband (data not
shown). In summary, we found no evidence of the pres-
ence of a mosaicism in the mother as explanation of her
phenotype.
The identiﬁcation of a microdeletion makes HCCS a
strong candidate gene for MLS. Therefore, we studied two
previously unreported female patients with MLS: 5-year-
old patient MS1 and 9-year-old patient MS2 (ﬁg. 3A–3C),
who both carry an apparently normal female karyotype.
By sequence analysis of the coding regions and exon-
intron boundaries of HCCS, we identiﬁed a heterozygous
c.589CrT (p.R197X) mutation in exon 6 of patient MS1,
as well as a heterozygous c.649CrT (p.R217C) mutation
in exon 7 of patient MS2 (ﬁg. 3D). The mutations were
found neither in the parents (paternity conﬁrmed) nor in
50 (for c.589CrT) or 110 (for c.649CrT) female controls
(data not shown). The ethnicity of the controls matched
that of the patients. The mutation found in patient MS2
affects the arginine residue at position 217 of the HCCS
protein, which is highly conserved across evolution in all
heme lyases,28 suggesting an important function of this
amino acid (ﬁg. 3E). In contrast, the sequence change in
patient MS1 causes a premature stop located 21 nt up-
stream of the last splicing-generated exon-exon junction,
which may deﬁne either a functional null allele due to
nonsense-mediated mRNA decay (NMD) or an HCCS pro-
tein lacking 72 C-terminal amino acids (D197–268). The
latter assumption is more likely, since mRNAs with pre-
mature termination codons located !50–55 nt upstream
of the most 3′ exon-exon junction are generally not tar-
geted for NMD.29
The S. cerevisiae strain B-8025 shows a severely depleted
respiratory function and is unable to grow on nonfer-
mentable carbon sources because of deletion of CYC3,
which encodes the yeast orthologue of the cytochrome c
heme lyase (Cyc3p).30 This deﬁciency has been shown to
be complemented by ectopically expressed human HCCS
protein.12 We expressed various human HCCS and yeast
886 The American Journal of Human Genetics Volume 79 November 2006 www.ajhg.org
Cyc3 proteins as GST-fusion proteins in yeast strain B-
8025 and analyzed their capacity to compensate for re-
spiratory deﬁciency. As expected, wild-type human HCCS
and yeast Cyc3 proteins were able to restore growth on
glycerol-containing medium. Notably, complementation
by yeast Cyc3p is only partial; that is probably because of
expression of a GST-fused protein. In contrast, expression
of either the C-terminally truncated HCCS protein (D197–
268) or HCCS carrying the missense mutation p.R217C
does not restore growth (ﬁg. 4A). By western-blot analysis
of protein extracts from the transformed B-8025 strains
grown in minimal medium, we conﬁrmed expression of
the four GST-fusion proteins: human wild-type HCCS,
D197–268, R217C, and yeast Cyc3p (ﬁg. 4B).
To investigate whether the mutated HCCS proteins are
still directed to mitochondria, we compared subcellular
localization of ectopically expressed wild-type HCCS with
mutated HCCS proteins. Indeed, we observed that N-ter-
minally HA-tagged wild-type HCCS protein is localized to
mitochondria in CHO-K1 cells (ﬁg. 5A–5C). Similarly, ec-
topically expressed HCCS with cysteine-217 (HCCS R217C)
is also targeted to mitochondria (ﬁg. 5D–5F), whereas the
HCCS mutant protein D197–268 was dispersed in the cy-
toplasm and nucleus (ﬁg. 5G–5I). We obtained similar re-
sults with wild-type HCCS proteins and the two mutants
carrying an N- or C-terminal EGFP tag or a C-terminal V5
tag (data not shown).
The HCCS gene product is supposed to act in a cell-
autonomous manner; therefore, functional nullisomy
should result in selective cell loss and consequent non-
random X inactivation in various tissues of heterozygous
females.We used themethylation-speciﬁc PCR at the poly-
morphic human AR locus to study the X-inactivation pat-
tern in all females carrying an HCCS mutation. In patients
MS1, MS2, II.7, the sister of II.7 (II.2), and the mother of
II.7 and II.2 (I.1), a skewed X chromosome–inactivation
pattern (85%–100%) in peripheral-blood cells was found
(ﬁg. 6A–6C). Consistently, a skewed X inactivation was
also observed in buccal mucosa cells of patient MS1, as
well as in ﬁbroblasts of patient II.7 (data not shown). Re-
sults from the X-inactivation studies for patients II.1 and
II.7 suggest that there is a selective disadvantage for cells
carrying the active maternal X chromosome (ﬁg. 6C).
Moreover, in both MS1 and MS2, the paternal X chro-
mosome was found to be preferentially inactivated (ﬁg.
6A and 6B). Accordingly, by RT-PCR analysis, we showed
that only HCCS mRNA transcribed from the wild-type al-
lele is detected in lymphoblastoid cells of patient MS1
(carrying p.R197X), suggesting that the nonsense muta-
tion occurred on the paternal allele (ﬁg. 6D).
Discussion
The ﬁndings that (1) HCCS maps within the smallestMLS
critical region—that is, HCCS is deleted in all patients
carrying chromosomal abnormalities, (2) HCCS is par-
tially deleted in two sisters with MLS and their asymp-
tomatic mother, and (3) loss-of-function pointmutations
occurred de novo in two patients with MLS provide
strong evidence of the involvement of the holocyto-
chrome c–type synthase in the pathogenesis of this syn-
drome. Thus, absence of heme-lyase activity in hemi-
zygous human males is most likely the cause of their in
utero lethality. Similarly, in vivo–generated deletions in-
volving the equivalent critical MLS region in the mouse
(MLSD), encompassing Hccs as well as parts of Mid1 and
Arhgap6, lead to lethality of hemizygous, homozygous,
and heterozygous embryos early in development. This
lethality can be rescued by overexpression of the human
HCCS gene from a BAC clone, providing proof that le-
thality is indeed due to loss of HCCS.31 Clearly, MLS be-
longs to the group of X-linked dominant male-lethal dis-
orders, including, for example, incontinentia pigmenti
and chondrodysplasia punctata 2.22
Functional analysis of both the nonsense (p.R197X) and
the missense (p.R217C) mutations revealed that (1) the
72 C-terminal amino acids are required for mitochondrial
targeting and (2) arginine-217 seems to be necessary for
proper function of HCCS. Consistently, an evolutionarily
conserved motif located within residues 190–216 of hu-
manHCCS was shown to be important for sorting of heme
lyases to the intermembrane space of mitochondria.28 The
arginine residue at position 217 is an invariant amino acid
in all HCCS proteins and is located next to one of the two
internal targeting signals (aa 190–216),28 which suggests
an important role of this residue for the integrity of the
holocytochrome c–type synthase.
Dysfunction of assembly factors of the mitochondrial
respiratory chain, such as the holocytochrome c–type syn-
thase, are known to cause various conditions with typical
symptoms of mitochondrial diseases, including myopa-
thy, encephalomyopathy, or cardiomyopathy, with a var-
iable age at disease onset.32,33 However, the data presented
here show, for the ﬁrst time (to our knowledge), that de-
ﬁciency of a mitochondrial housekeeping enzyme impli-
cated in OXPHOS may also cause a severe developmental
disorder with microphthalmia, sclerocornea, and areas of
aplastic skin. Thus, the complex phenotype of females
with MLS raises the question of a possible second function
of HCCS or its ﬁnal product that is not directly related to
OXPHOS.
The holocytochrome c–type synthase or heme lyase is
located at the outer surface of the inner mitochondrial
membrane and catalyzes the covalent attachment of heme
to apocytochrome c (and c1), which leads to the mature
holocytochrome c.30,34 In S. cerevisiae, two heme lyases
exist, the cytochrome c- (Cyc3p) and the cytochrome c1-
speciﬁc heme lyase (Cyt2p), whereas only a single heme
lyase is required for maturation of both cytochrome c and
c1 in higher eukaryotes.
11,13 Defects in either of the yeast
heme lyases result in loss of respiratory growth of the re-
spective strain.30,34
Cytochrome c is released frommitochondria in response
to a variety of intrinsic death-promoting stimuli, thereby
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leading to caspase-dependent death or apoptosis.15 Sub-
sequent binding of cytochrome c to the apoptotic prote-
ase-activating factor 1 (APAF-1) and the recruitment and
activation of procaspase-9 cleaves other caspases to exe-
cute apoptosis.35 Mice deﬁcient for cytochrome c as well
as knock-in mice expressing a mutant cytochrome c,which
retains its normal electron transfer function but is unable
to activate APAF-1, die perinatally because of severe de-
velopmental defects. Cells derived from both mice show
defects in apoptosis, because they are unable to form the
active apoptosome.36,37 Apoptosis is important for proper
neuronal development—for example, normal eye andbrain
development and impaired programmed cell death can
lead to severe developmental defects in human and/or
mouse.38–42 In the same line, a mutant strain of S. cerevisiae
lacking the cytochrome c–speciﬁc heme lyase Cyc3p is
more resistant to death than the wild type,43 which sug-
gests that the mature form of cytochrome c is required for
programmed cell death in yeast. Indeed, accumulation of
apocytochrome c in the cytosol eukaryotic cells has been
shown to cause inhibition of caspase-mediated apopto-
sis.44 Together, these data suggest that the release ofmature
cytochrome c is important for programmed cell death,
both in eukaryotic cells and in yeast. Accordingly, loss-of-
function mutations of HCCS in human are not only sup-
posed to give rise to severe functional deﬁcits in OXPHOS
in cells and tissues that rely mainly on mitochondrial en-
ergy supply, but they may also cause severe constraints
in the process of apoptosis. However, elimination of key
components of the intrinsic apoptotic cascade will not
prevent cell death, since caspase-independent or nonap-
optotic death—namely apoptosis-like death, autophagic
cell death, or necrosis—can still occur.45 Thus, absence
of components forming the apoptosome, such as cyto-
chrome c, will possibly result in a switch from apoptosis
to selective cell loss with a necrotic morphology.46 This
type of caspase-independent cell death is characterized by
loss of the mitochondrial transmembrane potential, low
intracellular ATP concentrations, and generation of reac-
tive oxygen species that occurred on disruption of the
mitochondrial electron-transport chain.47–50 Remarkably,
necrosis has even been found to substitute for caspase-
dependent apoptosis during embryonic development.51,52
Thus, we speculate that the majority of cells lacking a
functional copy of HCCS in heterozygous females will die
because of severe defects in OXPHOS. Nonetheless, mi-
tochondrial dysfunction and the resulting ATP depletion,
along with lack of holocytochrome c, which is required
to form the apoptosome, may push HCCS-deﬁcient cells
toward necrosis. It is of note that cell demise by necrosis
bears the danger of provoking a chronic chain reaction
of inﬂammation, with substantial damage to neighboring
cells.53,54
In conclusion, our data show, for the ﬁrst time, that
mutations in HCCS are associated with the MLS pheno-
type. Implication of cytochrome c—the ﬁnal HCCS prod-
uct—in both OXPHOS and caspase-dependent apoptosis
suggests that disturbance of the balance between necrosis
and apoptosis may be a key element in the development
of MLS symptoms in affected females. Further studies are
required for better understanding of the contribution of
pathogenic HCCS mutations and the individual pattern of
X inactivation in the development of MLS.
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